Literature DB >> 12426011

Bupropion exposures: clinical manifestations and medical outcome.

Martin G Belson1, Todd R Kelley.   

Abstract

Bupropion is an antidepressant and smoking cessation aid. Limited toxicological information exists for intentional and unintentional bupropion-only exposures. A retrospective review of all bupropion-only exposures reported to the Toxic Exposure Surveillance System from 1998 through 1999 was conducted. Data for the three bupropion products, Wellbutrin, Wellbutrin SR, and Zyban, included demographics, reason for exposure, clinical effects, therapy, and medical outcome. A total of 7,348 bupropion-only exposures were reported: 56% female and 61% unintentional. The majority of exposures involved Wellbutrin SR; however, Wellbutrin exposures involved a higher percentage of intentional overdoses and serious clinical effects. Clinical effects related to bupropion were noted in 2,247 (31%) exposures; 8% of all children <6-years-old compared to 46% of all teenagers. Seizures developed in 15% of all intentional exposures. Cardiovascular disturbances were extremely uncommon after overdose. The majority of unintentional bupropion-only exposures result in minimal or no clinical toxicity; however, a significant number of intentional overdoses result in seizures. Copyright 2002 Elsevier Science Inc

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426011     DOI: 10.1016/s0736-4679(02)00522-x

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  12 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 2.  Medically serious adverse effects of newer antidepressants.

Authors:  Rajnish Mago; Rajeev Mahajan; Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

3.  Fatal bupropion overdose with post mortem blood concentrations.

Authors:  Henry A Spiller; Edward Bottei; Linda Kalin
Journal:  Forensic Sci Med Pathol       Date:  2007-08-22       Impact factor: 2.007

4.  The outcome of unintentional pediatric bupropion ingestions: a NPDS database review.

Authors:  Michael C Beuhler; Henry A Spiller; Howell C Sasser
Journal:  J Med Toxicol       Date:  2010-03

Review 5.  Drug and non-drug treatments of children with ADHD and tic disorders.

Authors:  Yann Poncin; Denis G Sukhodolsky; Joseph McGuire; Lawrence Scahill
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-06       Impact factor: 4.785

Review 6.  Contemporary assessment and pharmacotherapy of Tourette syndrome.

Authors:  Lawrence Scahill; Gerald Erenberg; Cheston M Berlin; Cathy Budman; Barbara J Coffey; Joseph Jankovic; Louise Kiessling; Robert A King; Roger Kurlan; Anthony Lang; Jonathan Mink; Tanya Murphy; Samual Zinner; John Walkup
Journal:  NeuroRx       Date:  2006-04

7.  Pediatric Bupropion Ingestions in Adolescents vs. Younger Children-a Tale of Two Populations.

Authors:  Steve Offerman; Michael Levine; Jasmin Gosen; Stephen H Thomas
Journal:  J Med Toxicol       Date:  2019-11-11

8.  In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs.

Authors:  Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Mohamed O Hamad; Peter A Crooks; Audra L Stinchcomb
Journal:  Eur J Pharm Sci       Date:  2008-01-31       Impact factor: 4.384

9.  Successful Management of Adolescent Bupropion Overdose with Intravenous Lipid Emulsion Therapy.

Authors:  Kasha Bornstein; Tim Montrief; Mehruba Anwar Parris
Journal:  J Pediatr Intensive Care       Date:  2019-07-25

Review 10.  Antidepressants for smoking cessation.

Authors:  John R Hughes; Lindsay F Stead; Jamie Hartmann-Boyce; Kate Cahill; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.